HRAS mutations were known to be oncogenic; it was demonstrated in vitro that mutant HRAS hyperactivated MAPK and mTOR pathways in various cancer cell lines including lung, bladder, and oesophageal cancer [30,31]. This evidence concerns the gene MTOR and cancer.